Centrient Pharmaceuticals
Dr. Manja Boerman currently serves as a Member of The Supervisory Board at Syngene International Limited and DINAMIQS, and as a Member of The Supervisory Board at Centrient Pharmaceuticals since September 2021. Recently, Dr. Boerman held the position of Interim Chief Executive Officer at Prothya Biosolutions. Previous roles include President of Catalent Biomodalities and President of Catalent Cell and Gene Therapy until December 2023, as well as Managing Director at Aesica Pharmaceuticals Ltd. Dr. Boerman's extensive experience in the biopharmaceutical sector also includes leadership roles at Opnostics, Charles River Laboratories, Patheon Biologics, and DSM. Dr. Boerman holds a PhD in Biochemistry from the University at Buffalo.
This person is not in any teams
This person is not in any offices
Centrient Pharmaceuticals
2 followers
Centrient Pharmaceuticals is the global business-to-business leader in sustainable, enzymatic antibiotics, next generation statins and anti-fungals. We produce and sell intermediates and active pharmaceutical ingredients (APIs), as well as our own tablets, capsules and other finished dosage forms (FDFs). We stand proudly at the centre of modern healthcare, as a maker of essential and life-saving medicines. With our commitment to Quality, Reliability and Sustainability at the heart of everything we do, our over 1,800 employees work continuously to meet our customers’ needs. We work towards a sustainable future by actively participating in the fight against antimicrobial resistance. Founded 150 years ago as the ‘Nederlandsche Gist- en Spiritusfabriek’, our company was known as Gist Brocades and more recently DSM Sinochem Pharmaceuticals. Headquartered in Rotterdam (Netherlands), we have production facilities and sales offices in China, India, the Netherlands, Spain, the United States and Mexico. Centrient Pharmaceuticals is owned by Bain Capital Private Equity, a leading global private investment firm.